In order to validate Pak1 as a marker of acquired mechanisms of resistance also in patients’ cohort, the evaluation of PAK1 expression might be investigated in future studies in tumor biopsies of patients with disease progression after ER+ plus CDK4/6i therapy. The gene discussed is CDK4; the disease is neoplasm.